Eli Lilly has secured FDA approval for its oral GLP-1 medication, Foundayo, marking a significant advancement in the competitive weight-loss drug market. The pill will be available through LillyDirect and pharmacies starting Monday, with pricing set at $25 for insured patients and between $149 and $349 for those paying out of pocket. This launch comes just months after Novo Nordisk’s Wegovy pill, intensifying the rivalry between the two pharmaceutical giants.
The introduction of Foundayo is poised to disrupt the weight-loss sector, particularly as it offers a more accessible alternative to injectable treatments like Zepbound. Analysts project Foundayo could generate $14.79 billion in sales by 2030, although it trails behind Zepbound and Mounjaro in potential revenue. Lilly’s focus on affordability and ease of use may attract a broader patient base, especially seniors on Medicare, who will see reduced costs for GLP-1 medications.
For market professionals, the successful uptake of Foundayo will be critical for Lilly’s stock recovery, which has seen a 14% decline this year. Analysts will closely monitor prescription trends as an indicator of market performance, while the anticipated results from Lilly’s obesity shot, retatrutide, could further bolster its position in the obesity treatment landscape.
Source: cnbc.com